Maciej Banach, Poland

Maciej Banach, Poland

Biography

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education
of the Republic of Poland (2010-2012). He is a President of Polish Mother’s Memorial Hospital –
Research Institute (PMMHRI) (February 2014-), Head of Cardiovascular Research Centre at
University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL)
and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension
(2008-) at the Medical University of Lodz and Professor in the Department of Nephrology,
Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University
Hospital in Lodz, Poland (2009-).
He is member of the Executive Committee of European Atherosclerosis Society (EAS) working as an
Advisor in Matters related to European Union Relations/Contacts, and the International
Atherosclerosis Society (IAS) Regional Federation Executive Committee Member for Europe. He is a
Founder and Head of the Polish Lipid Association (PoLA) (2011-) – the official partner of National
Lipid Association (NLA, US) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the
founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC; lbpmcgroup.umed.pl)
Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues
in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the
International Lipid Expert Panel (ILEP; ilep.eu) (2015-), which has been founded to prepare
recommendations in the area of preventive cardiology in the most debatable issues that have not been
covered in the existing guidelines. He is a member of 2 largest worldwide databases – the Global
Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases
Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and
President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health
research institutes and over 40 medical business representatives in Poland with main aim to make
innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at
Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania
(2014-).
Prof. Banach has published over 750 original articles, reviews, editorials and book chapters in the field
of hypertension, dyslipidemia, cardiology, cardiac surgery, and risk stratification (648 acc. to PubMed,
752 acc. to Web of Knowledge/Publons, 563 acc. to SCOPUS, 804 acc. to ResearchGate – RG Score:
52.53, and >1000 acc. to Google Scholar). His combined IF (for only full-text manuscripts) is over
7000 pts., number of citations: 10,934 (acc. Web of Science Core Collection/Publons), 11,876 (acc.
SCOPUS), 11,773 (acc. ResearchGate), and 17,117 (acc. Google Scholar), Hirsch’s Index = 45
(WoS/Publons), 48 (SCOPUS), 50 (ResearchGate) and 59 (i10-index: 345) (Google Scholar) – being
within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and
Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 25 TOP
Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of
lipids (2), statin therapy (7), cholesterol (13), and HDL cholesterol (10).
He is Editor-in-Chief of the Archives of Medical Science (IF2018 = 2.380), Archives of Medical
Science – Civilization Diseases, and Archives of Medical Science – Atherosclerotic Diseases, Scientific
Coordinator of the HeartBeat Journal, Regional Associate Editor of European Heart Journal –
Quality of Care and Clinical Outcomes, Deputy Editor of Thyroid Research and Clinical and
Experimental Medical Letters (2007-2012), Associate/Section Editor of Recent Patents on
Cardiovascular Drugs Discovery, BMC Medicine, Scientific Reports, Biomed Research International
and The Open Atherosclerosis & Thrombosis Journal, and member of Editorial Advisory Board of
over 40 international medical journals. He is also a Faculty member of F1000 prime. He is Reviewer
of over 80 international journals, including New England Journal of Medicine, European Heart
Journal, Lancet Diabetes & Endocrinology, Circulation, Circulation Research, British Medical
Journal and Journal of American College of Cardiology; editor or author of 31 books (102 chapters).
He is also a Scientific President (2016-) of the Termedia Publishing House, being responsible for over
50 scientific journals.
Participation in clinical trials since 2005: (1) IPDACS Trial (Incidence and Predictors of Delirium
After Cardiac Surgery) (NCT00784576) (study coordinator [SC]); (2) ACT 2 Trial with RSD1235 –
vernakalant (principal investigator [PI]); (3) The Influence of Atorvastatin on the Parameters of
Inflammation and the Function of Left Ventricle (NCT01015144) (PI); (4) SWEEP TRIAL (Study to
Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia
Associated With Chronic Kidney Disease) (PI); (5) SWEEP OLE Trial (PI); (6) STIPPARE Trial
(Simvastatin in the Treatment of Isolated arterial hyPertension and Prevention of cARdiovascular
Events) (NCT01017835) (PI); (7) FIRST Trial (Ferumoxytol Compared to Iron Sucrose Trial: A
Randomized, Multicenter Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron
Deficiency Anemia in Adult Subjects with Chronic Kidney Disease); (8) FER-CKD Trial (An openlabel
multicentre, randomised 3-arm study to investigate the comparative efficacy and safety of
intravenous ferric carboxymaltose vesus oral iron for the treatment of iron deficiency anaemia in
subjects with non-dialysis-dependent chronic kidney disease) (Co-Investigator [CPI]); (9) FOURIER
(Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk)
trial (PI); (10) ENSURE-AF (national PI [NPI]); (10) BetOnMACE trial (RVX222-CS-015) (NPI);
(11) ODDYSEY APPRISE Trial (LPS14245) (NPI); (12) CLEAR Harmony trial (Evaluation of
Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High
CV Risk) (PI); (13) CLEAR Harmony OLE Trial (PI); (14) CLEAR Outcomes Study (1002-043)
(NPI); (15) Da Vinci Study (co-NPI), ODDYSEY Kids (NPI), (16) VESALIUS-REAL Trial with
evolocumab (NPI), (17) LIPIDOGRAM & LIPIDOGEN study (co-PI), (18) FHSC Registry (NPI),
(19) TERCET Registry.
He is a fellow of the Council for High Blood Pressure Research of the American Heart Association
(FAHA), National Lipid Association (FNLA), American Society of Angiology (FASA), European
Society of Cardiology (FESC), Royal Society for Public Health (FRSPH) and Society of Geriatric
Cardiology (FSGC; 2008-2010). He is a member of the working-core of Alliance for Biomedical
Research/European Council for Health Research (2011-2013 and 2016- being as a EAS
representative), steering committee of European Innovation Partnership in Active and Healthy Ageing
(2010-2012) at the European Commission, member of the European Commission’s Scientific Panel for
Health (SPH) (2014-2017), and steering committee of Centre for Good Aging / Healthy Ageing
Research Center (HARC) at the Medical University of Lodz, member of Committee for Public Health
of the Polish Academy of Sciences, member of the Scientific Board of Institute of Sport in Warsaw,
Poland, and the Presiding Board of Scientific Committee of the Polish Ministry of Health (2015-). He
is an expert of the European Medicines Agency (EMA, 2018-), and member of prestigious EU
Academy of Sciences (EUAS; 2018-).
He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Institute of
Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara
(2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical
University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017),
“Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for
the development of science in the field of healthcare – founded by the Heath Manager journal
(Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition
for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of
Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), 18 individual and
group scientific awards of President of Medical University of Lodz (2009-2016); START Award
(2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal
Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007)
and Heart Failure Association of ESC (2005, 2007).
His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension,
new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy,
prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare
diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD
therapy.